{"retracted":false,"update":{"timestamp":1454457600000,"doi":"10.1186/s13063-016-1195-6","type":"correction"},"doi":"10.1186/s13063-015-1101-7","journal":"Trials","publisher":"Springer Nature","title":"Erratum to: â€˜Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial"}
